The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Abstract
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 3×
“1.(10) However, given the heterogeneity of high-grade gliomas and the difficulty in measuring some lesions, a maximum of five of the largest lesions may be measured.”
BackgroundResultInfluentialRadiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Self-citationModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Increasing evidence suggests that anti-VEGF therapy may increase the tendency of tumor cells to co-opt existing blood vessels, resulting in an invasive nonenhancing phenotype.(52-54) Unlike the Macdonald Criteria, which do not take into account progressive nonenhancing disease, the new response assessment will conside…”
BackgroundBevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Self-citationPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Self-citation
Research works printed but not linked: 9
- 10.3171/jns.1996.84.2.0174 · doi:10.3171/jns.1996.84.2.0174
- 10.1016/j.surneu.2006.04.015 · doi:10.1016/j.surneu.2006.04.015
- 10.1002/ana.410170607 · doi:10.1002/ana.410170607
- 10.1148/radiology.204.3.9280269 · doi:10.1148/radiology.204.3.9280269
- Matheus MG, 2004, Am J Neuroradiol, 25, 1211
- Floeth FW, 2001, Am J Neuroradiol, 22, 1517
- 10.1023/A:1014571900854 · doi:10.1023/a:1014571900854
- 10.1016/j.crad.2006.09.012 · doi:10.1016/j.crad.2006.09.012
- 10.1055/s-0028-1083696 · doi:10.1055/s-0028-1083696
Cited by
Items 101–138 of 138
Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients
Osti, D., Del Bene, M., Rappa, G., Santos, M., Matafora, V., Richichi, C., Faletti, S., Beznoussenko, G. V., Mironov, A., Bachi, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1941 · Cited by 267
Galldiks, N., Dunkl, V., Stoffels, G., Hutterer, M., Rapp, M., Sabel, M., Reifenberger, G., Kebir, S., Dorn, F., Blau, T., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2959-4 · Cited by 266
Nayak, L., Molinaro, A. M., Peters, K., Clarke, J. L., Jordan, J. T., de Groot, J., Nghiemphu, L., Kaley, T., Colman, H., McCluskey, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2500 · Cited by 265
Self-citationChiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D. A., Reardon, D. A., Wen, P., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 263
Self-citationUnderstanding high grade glioma: Molecular mechanism, therapy and comprehensive management
Wang, Y., & Jiang, T. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.12.024 · Cited by 260
van Dijken, B. R. J., van Laar, P. J., Holtman, G. A., & van der Hoorn, A. (2017) · European Radiology · doi:10.1007/s00330-017-4789-9 · Cited by 259
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., et al. (2019) · Nature · doi:10.1038/s41586-019-1600-x · Cited by 259
Chukwueke, U. N., & Wen, P. Y. (2019) · CNS Oncology · doi:10.2217/cns-2018-0007 · Cited by 256
Self-citationPhase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
Dunbar, E. M., Coats, B. S., Shroads, A. L., Langaee, T., Lew, A., Forder, J. R., Shuster, J. J., Wagner, D. A., & Stacpoole, P. W. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0047-4 · Cited by 241
Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3052 · Cited by 190
“Progression of disease was confirmed by either tissue diagnosis or standard response criteria (28).”
Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
Geoerger, B., Zwaan, C. M., Marshall, L. V., Michon, J., Bourdeaut, F., Casanova, M., Corradini, N., Rossato, G., Farid-Kapadia, M., Shemesh, C. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30693-x · Cited by 171
Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., Sankhala, K., Mita, A., Elian, K., Bouchard, D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0566 · Cited by 168
Gahramanov, S., Muldoon, L. L., Varallyay, C. G., Li, X., Kraemer, D. F., Fu, R., Hamilton, B. E., Rooney, W. D., & Neuwelt, E. A. (2013) · Radiology · doi:10.1148/radiol.12111472 · Cited by 162
BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
Brastianos, P. K., Twohy, E., Geyer, S., Gerstner, E. R., Kaufmann, T. J., Tabrizi, S., Kabat, B., Thierauf, J., Ruff, M. W., Bota, D. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213329 · Cited by 146
Self-citationElshafeey, N., Kotrotsou, A., Hassan, A., Elshafei, N., Hassan, I., Ahmed, S., Abrol, S., Agarwal, A., El Salek, K., Bergamaschi, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11007-0 · Cited by 147
Ellingson, B. M. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0506-0 · Cited by 132
Schipmann, S., Müther, M., Stögbauer, L., Zimmer, S., Brokinkel, B., Holling, M., Grauer, O., Suero Molina, E., Warneke, N., & Stummer, W. (2021) · Journal of Neurosurgery · doi:10.3171/2019.11.jns192443 · Cited by 121
Ananda, S., Nowak, A. K., Cher, L., Dowling, A., Brown, C., Simes, J., & Rosenthal, M. A. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.02.026 · Cited by 116
Natsume, A., Arakawa, Y., Narita, Y., Sugiyama, K., Hata, N., Muragaki, Y., Shinojima, N., Kumabe, T., Saito, R., Motomura, K., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac155 · Cited by 93
Clinically feasible NODDI characterization of glioma using multiband EPI at 7 T
Wen, Q., Kelley, D. A. C., Banerjee, S., Lupo, J. M., Chang, S. M., Xu, D., Hess, C. P., & Nelson, S. J. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.08.017 · Cited by 88
Self-citationHuang, J., Campian, J. L., Gujar, A. D., Tran, D. D., Lockhart, A. C., DeWees, T. A., Tsien, C. I., & Kim, A. H. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2104-2 · Cited by 79
Self-citationPeng, T., Ma, X., Hua, W., Wang, C., Chu, Y., Sun, M., Fermi, V., Hamelmann, S., Lindner, K., Shao, C., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.01.002 · Cited by 86
Thivat, E., Casile, M., Moreau, J., Molnar, I., Dufort, S., Seddik, K., Le Duc, G., De Beaumont, O., Loeffler, M., Durando, X., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10829-y · Cited by 76
Halatsch, M.-E., Kast, R. E., Karpel-Massler, G., Mayer, B., Zolk, O., Schmitz, B., Scheuerle, A., Maier, L., Bullinger, L., Mayer-Steinacker, R., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab075 · Cited by 74
Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad031 · Cited by 73
Qin, L., Li, X., Stroiney, A., Qu, J., Helgager, J., Reardon, D. A., & Young, G. S. (2017) · Neuroradiology · doi:10.1007/s00234-016-1769-8 · Cited by 64
Self-citationLorgis, V., Maura, G., Coppa, G., Hassani, K., Taillandier, L., Chauffert, B., Apetoh, L., Ladoire, S., & Ghiringhelli, F. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0748-5 · Cited by 60
Suchorska, B., Schüller, U., Biczok, A., Lenski, M., Albert, N. L., Giese, A., Kreth, F.-W., Ertl-Wagner, B., Tonn, J.-C., & Ingrisch, M. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.019 · Cited by 59
Reardon, D. A., Lassman, A. B., Schiff, D., Yunus, S. A., Gerstner, E. R., Cloughesy, T. F., Lee, E. Q., Gaffey, S. C., Barrs, J., Bruno, J., et al. (2018) · Cancer · doi:10.1002/cncr.31172 · Cited by 50
Self-citationRecurrent glioblastoma: a fresh look at current therapies and emerging novel approaches
Gilbert, M. R. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.09.008 · Cited by 45
Self-citationFathi Kazerooni, A., Akbari, H., Shukla, G., Badve, C., Rudie, J. D., Sako, C., Rathore, S., Bakas, S., Pati, S., Singh, A., et al. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00121 · Cited by 39
“at institution 2), in compliance with criteria for tumor progression provided by the Response Assessment in Neuro-Oncology Working Group.(30) RP was determined by neuroradiologists (S.”
MethodBoxerman, J. L., Zhang, Z., Safriel, Y., Rogg, J. M., Wolf, R. L., Mohan, S., Marques, H., Sorensen, A. G., Gilbert, M. R., & Barboriak, D. P. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy049 · Cited by 35
Self-citationPhase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up
Kang, Z., Li, S., Kang, X., Deng, J., Yang, H., Chen, F., Jiang, J., Zhang, J., & Li, W. (2023) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2022.0762 · Cited by 37
Schmainda, K. M., Prah, M. A., Marques, H., Kim, E., Barboriak, D. P., & Boxerman, J. L. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noaa167 · Cited by 28
The role of systemic and targeted therapies in brain metastases
Franceschi, E., Bartolotti, M., Poggi, R., Battista, M. D., Palleschi, D., & Brandes, A. A. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.856760 · Cited by 7
Magnetic resonance imaging techniques for monitoring glioma response to chemoradiotherapy
Lawrence, L. S. P., Maralani, P. J., Das, S., Sahgal, A., Stanisz, G. J., & Lau, A. Z. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04856-3 · Cited by 4
Sonni, I., Garibotto, V., Iagaru, A., Das, D., & Massoud, T. (2018) · PET/MRI in Oncology · doi:10.1007/978-3-319-68517-5_11 · Cited by 3
Metadata
- Authors
- Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., Tsien, C., Mikkelsen, T., Wong, E. T., Chamberlain, M. C., Stupp, R., Lamborn, K. R., Vogelbaum, M. A., van den Bent, M. J., & Chang, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-10
- Volume
- 28
- Issue
- 11
- Pages
- 1963-1972
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162643152
- Cited by
- 3,836
- References
- 49
- FWCI
- 69.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.